舍曲林联合阿立哌唑治疗强迫症的临床观察

Clinical observation of combined with sertraline and aripiprazole in obsessivecompulsive disorder

目的探讨舍曲林联合阿立哌唑治疗强迫症的临床疗效及耐受性。方法 86例强迫症患者随机分为观察组(n=43)和对照组(n=43),观察组用舍曲林和阿立哌唑联合治疗,对照组单用舍曲林治疗,观察治疗12周。于治疗前、治疗4周末、8周末、12周末分别用耶鲁布朗强迫量表(Y-BOCS)评定强迫症状、用汉密尔顿焦虑量表(HAMA)评定焦虑症状、用副反应量表(TESS)评定治疗4周末、8周末、12周末的药物不良反应。结果 Y-BOCS总分治疗前、治疗4周末两组间差异无统计学意义(P>0.05),治疗8周末、12周末两组间差异有统计学意义(P<0.05);HAMA总分治疗前两组差异无统计学意义(P>0.05),治疗4周末、8周末、12周末差异均有统计学意义(P<0.05);治疗4周末、8周末、12周末两组间TESS总分差异均无统计学意义(P>0.05)。结论舍曲林联合阿立哌唑治疗强迫症效果良好,不良反应无增加。

Objective To explore the clinical efficacy and tolerance of sertraline combined with aripiprazole in the treatment ofobsessive compulsive disorder.Methods Eighty-six patients with obsessive compulsive disorder were randomly divided intoobservation group （n=43） and control group （n=43）.The patients in observation group were treated with sertraline and aripiprazole,while the patients in the control group were treated with sertraline,then the two groups were treated and observed for 12 weeks.Before treatment and at the end of 4,8,and 12 weeks treatment,the efficacy was assessed with Yale-Brow obsessive compulsive scale（Y-BOCS） and Hamilton rating scale for anxiety （HAMA）.The adverse reactions were assessed with the treatment emergentsymptoms scale （TESS） at the end of 4,8,and 12 weeks treatment.Results There was no significant difference in total score ofY-BOCS between the two groups before treatment and after the end of 4 weeks treatment （P 0.05）,there was significant difference intotal score of Y-BOCS at the end of 8 and 12 weeks treatment （P 0.05）.There was no significant difference in total score of HAMAbetween the two groups before treatment （P 0.05）;At the end of 4,8,and 12 weeks treatment,total scores of HAMA weresignificantly different （P 0.05）;At the end of 4,8,and 12 weeks treatment,TESS scores were not significantly different （P 0.05）.Conclusion Clinical observation of sertraline combined with aripiprazole in obsessive compulsive disorder is favorable,at the sametime,there is no increase in adverse reactions.